DCVC Announcements DCVC closes $700 million+ in new funds for a healthier planet and healthier lives; releases second-annual Deep Tech Opportunities Report and first-annual DCVC Climate Impact Report
News DCVC Bio III closes at $400 million By Dr. John Hamer, Dr. Kiersten Stead, Matthew Ocko, Zachary Bogue
News Umoja gets FDA approval to begin clinical trials of its transformative in vivo gene therapy for cancer By Dr. Kiersten Stead, Dr. John Hamer
News DCVC co-leads $12.5 million financing for Kanvas Biosciences to boost immunotherapy by mapping beneficial gut bacteria By Jason Pontin
News MycoWorks expands to address the soaring need for high-end leather alternatives By Dr. Kiersten Stead
News With Assets from Federation Bio, Kanvas Aims to Replace Imprecise Microbiome Therapies with a Single, Rationally Designed Pill By Jason Pontin
News DCVC leads $12M financing for Kanvas Biosciences to map the human body’s undiscovered territory: the microbiome By Jason Pontin
News DCVC leads $13 million seed funding for ShennonBio—revolutionizing immunotherapy through immune cell profiling at unprecedented accuracy, speed By James Hardiman
News Biology-as-a-Platform in the Fight Against Cancer: Freenome Raises $270m Series C By Zachary Bogue
News Life sciences and Deep Tech: The next set of solutions to the next set of problems By Dr. Kiersten Stead, Dr. John Hamer, Matthew Ocko, Zachary Bogue
Thoughts An Update on How Deep Tech is Arming the Fight Against COVID-19 By Matthew Ocko, Zachary Bogue
Thoughts Powering a Comprehensive Response to the COVID-19 Crisis Through Deep Tech By Matthew Ocko, Zachary Bogue
News Reimagining biologics: AbCellera and Novartis partner to find new disease treatments By Dr. John Hamer
News AbCellera Raises $10M Series A: Deep Search for the Immune System By Matthew Ocko, Zachary Bogue
News DCVC Bio leads GenEdit’s $8.5 Million Seed Round: Safe, efficient CRISPR and gene therapy delivery platform proven across multiple diseases and cell types By Matthew Ocko, Zachary Bogue